• Eli Lilly and Company recently received a positive opinion from the European Medicines Agency’s human medicines committee for Jaypirca (pirtobrutinib) to treat adults with chronic lymphocytic leukemia across all lines of therapy, while U.S. Medicare approved a new GLP-1 Bridge program that will give eligible patients access to Zepbound and Foundayo weight-management drugs for a US$50 monthly copay.
• Together, these developments highlight how Lilly is extending its reach in both oncology and obesity care, pairing a broader CLL treatment window in Europe with expanded U.S. reimbursement that could materially deepen access to its incretin portfolio.
• Next, we’ll explore how the European Jaypirca endorsement may influence Eli Lilly’s existing investment narrative around growth, risk, and diversification.

Find 44 companies with promising cash flow potential yet trading below their fair value.

Eli Lilly Investment Narrative Recap

To own Eli Lilly, you need to believe its obesity and diabetes franchise can keep driving results while newer areas like oncology and neurodegeneration steadily broaden the base. The Jaypirca opinion in Europe and Medicare’s GLP‑1 Bridge program mainly support this existing narrative by reinforcing access and diversification; they do not remove the key near term risk that pricing pressure and reimbursement decisions could crimp profitability on Lilly’s highest profile incretin drugs.

Among the recent announcements, the Medicare GLP‑1 Bridge program is most relevant here, because it directly addresses access and reimbursement for Zepbound and Foundayo at a US$50 monthly copay. That expanded coverage works alongside Jaypirca’s potential EU label expansion to underline a central catalyst: Lilly is trying to deepen real world uptake of its incretin portfolio while adding incremental growth drivers in oncology, which matters if payers become more aggressive on obesity drug costs.

Yet, even with these positives, investors should be aware that pricing reform for obesity drugs could still...

Eli Lilly's narrative projects $113.8 billion revenue and $46.8 billion earnings by 2029.

Uncover how Eli Lilly's forecasts yield a $1219 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already assuming earnings of about US$40.2 billion by 2029 and a lower 24x PE, which reflects a more cautious view than the base case you just read, especially around the risk that escalating safety and pricing scrutiny on obesity drugs could raise R&D costs and pressure margins over time.

Explore 19 other fair value estimates on Eli Lilly - why the stock might be worth 26% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Eli Lilly research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.